Join to View Full Profile
450 Brookine Ave, D1220Dana Farber Cancer InstituteBoston, MA 02215
Phone+1 617-632-6942
Fax+1 617-632-5370
Dr. Wolpin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2006- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2001 - 2004
Harvard Medical SchoolClass of 2001
Certifications & Licensure
MA State Medical License 2003 - 2026
NH State Medical License 2024 - 2026
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer Start of enrollment: 2009 May 01
- RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer Start of enrollment: 2010 Feb 01
- Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer Start of enrollment: 2011 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic C...Jennifer J Knox, Grainne O'Kane, Daniel King, Daniel Laheru, Amber N Habowski
Journal of Clinical Oncology. 2025-09-10 - Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.Rishi Surana, Micaela Morgado, Ashwin Somasundaram, Bruno Bockorny, Colin D Weekes
JCO Precision Oncology. 2025-09-01 - A neomorphic protein interface catalyzes covalent inhibition of RASaspartic acid in tumors.Caroline Weller, G Leslie Burnett, Lingyan Jiang, Sujata Chakraborty, Dongyu Zhang
Science. 2025-07-24
Journal Articles
- Diabetes, Weight Change, and Pancreatic Cancer RiskDouglas A Rubinson, Kimmie Ng, Meir J Stampfer, Brian M Wolpin, JAMA Oncology
- Germline Cancer Susceptibility Gene Variants, Somatic Second Hits, and Survival Outcomes in Patients with Resected Pancreatic CancerRichard F Dunne, Leona A Doyle, William C Hahn, Jason L Hornick, Andrea J Bullock, Sapna Syngal, Albert C Koong, Natalia Khalaf, Brian M Wolpin, Douglas A Rubinson, Da..., Nature
- Altered Exocrine Function Can Drive Adipose Wasting in Early Pancreatic CancerJared R Mayers, Naoki Takahashi, Nicole Lopez, Brian M Wolpin, Nature
Authored Content
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Join now to see all
Press Mentions
Early-Career Physician-Scientists Receive Major Support from Damon Runyon Cancer Research FoundationJuly 13th, 2025- Tumor-Treating Electrical Fields Improve Overall Survival in Pancreatic CancerJune 3rd, 2025
- Survival in Unresectable Pancreatic Cancer Improved with Tumor Treating FieldsJune 2nd, 2025
- Join now to see all
Grant Support
- Altered metabolism and machine learning for pancreatic cancer early detectionDANA-FARBER CANCER INST2022–2027
- Altered metabolism and machine learning for pancreatic cancer early detectionDANA-FARBER CANCER INST2022–2027
- Cohort Study Of Biochemical And Genetic Risk Factors For Pancreatic CancerNational Cancer Institute2009–2011
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
